15.08.2014 Ruxolitinib for myelofibrosis: indication of considerable added benefit Advantages in symptoms and survival time in comparison with “best supportive care” Press release
11.04.2011 Treatment for stroke: dipyridamole plus ASA offers no advantages Additional benefit versus ASA and clopidogrel is not proven / Major bleeding occurs more often with combination therapy Press release